TY  - JOUR
AU  - Lukić, Nikola
AU  - Mačvanin, Mirjana T.
AU  - Gluvić, Zoran
AU  - Rizzo, Manfredi
AU  - Radak, Đorđe
AU  - Suri, Jasjit S.
AU  - Isenović, Esma R.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12022
AB  - Type 2 diabetes mellitus (T2DM) has become a worldwide concern in recent years, primarily in highly developed Western societies. T2DM causes systemic complications, such as atherosclerotic heart disease, ischemic stroke, peripheral artery disease, kidney failure, and diabetes-related maculopathy and retinopathy. The growing number of T2DM patients and the treatment of long-term T2DM-related complications pressurize and exhaust public healthcare systems. As a result, strategies for combating T2DM and developing novel drugs are critical global public health requirements. Aside from preventive measures, which are still the most effective way to prevent T2DM, novel and highly effective therapies are emerging. In the spotlight of next-generation T2DM treatment, sodium-glucose co-transporter 2 (SGLT-2) inhibitors are promoted as the most efficient perspective therapy. SGLT-2 inhibitors (SGLT2i) include phlorizin derivatives, such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT-2, along with SGLT-1, is a member of the SGLT family of proteins that play a role in glucose absorption via active transport mediated by Na+ /K+ ATPase. SGLT-2 is only found in the kidney, specifically the proximal tubule, and is responsible for more than 90% glucose absorption. Inhibition of SGLT-2 reduces glucose absorption, and consequently increases urinary glucose excretion, decreasing blood glucose levels. Thus, the inhibition of SGLT-2 activity ultimately alleviates T2DM-related symptoms and prevents or delays systemic T2DM-associated chronic complications. This review aimed to provide a more detailed understanding of the effects of SGLT2i responsible for the acute improvement in blood glucose regulation, a prerequisite for T2DM-associated cardiovascular complications control.
T2  - Current Medicinal Chemistry
T1  - SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
VL  - 31
DO  - 10.2174/0109298673251493231011192520
ER  - 

@article{
author = "Lukić, Nikola and Mačvanin, Mirjana T. and Gluvić, Zoran and Rizzo, Manfredi and Radak, Đorđe and Suri, Jasjit S. and Isenović, Esma R.",
year = "2023",
abstract = "Type 2 diabetes mellitus (T2DM) has become a worldwide concern in recent years, primarily in highly developed Western societies. T2DM causes systemic complications, such as atherosclerotic heart disease, ischemic stroke, peripheral artery disease, kidney failure, and diabetes-related maculopathy and retinopathy. The growing number of T2DM patients and the treatment of long-term T2DM-related complications pressurize and exhaust public healthcare systems. As a result, strategies for combating T2DM and developing novel drugs are critical global public health requirements. Aside from preventive measures, which are still the most effective way to prevent T2DM, novel and highly effective therapies are emerging. In the spotlight of next-generation T2DM treatment, sodium-glucose co-transporter 2 (SGLT-2) inhibitors are promoted as the most efficient perspective therapy. SGLT-2 inhibitors (SGLT2i) include phlorizin derivatives, such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT-2, along with SGLT-1, is a member of the SGLT family of proteins that play a role in glucose absorption via active transport mediated by Na+ /K+ ATPase. SGLT-2 is only found in the kidney, specifically the proximal tubule, and is responsible for more than 90% glucose absorption. Inhibition of SGLT-2 reduces glucose absorption, and consequently increases urinary glucose excretion, decreasing blood glucose levels. Thus, the inhibition of SGLT-2 activity ultimately alleviates T2DM-related symptoms and prevents or delays systemic T2DM-associated chronic complications. This review aimed to provide a more detailed understanding of the effects of SGLT2i responsible for the acute improvement in blood glucose regulation, a prerequisite for T2DM-associated cardiovascular complications control.",
journal = "Current Medicinal Chemistry",
title = "SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus",
volume = "31",
doi = "10.2174/0109298673251493231011192520"
}

Lukić, N., Mačvanin, M. T., Gluvić, Z., Rizzo, M., Radak, Đ., Suri, J. S.,& Isenović, E. R.. (2023). SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus. in Current Medicinal Chemistry, 31.
https://doi.org/10.2174/0109298673251493231011192520

Lukić N, Mačvanin MT, Gluvić Z, Rizzo M, Radak Đ, Suri JS, Isenović ER. SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus. in Current Medicinal Chemistry. 2023;31.
doi:10.2174/0109298673251493231011192520 .

Lukić, Nikola, Mačvanin, Mirjana T., Gluvić, Zoran, Rizzo, Manfredi, Radak, Đorđe, Suri, Jasjit S., Isenović, Esma R., "SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus" in Current Medicinal Chemistry, 31 (2023),
https://doi.org/10.2174/0109298673251493231011192520 . .

TY  - JOUR
AU  - Lukić, Nikola
AU  - Stanković, Aleksandra
AU  - Dinčić, Evica
AU  - Bundalo, Maja M.
AU  - Krsmanovic, Z.
AU  - Alavantić, Dragan
AU  - Živković, Maja
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5506
AB  - The function of peroxisome proliferator-activated receptor gamma (PPAR gamma) in immune regulation, as well as in anti-inflammatory and anti-proliferative actions towards T lymphocytes, has been reported. A potential role of PPARs in multiple sclerosis (MS) was suggested. The aim of this study was to investigate if there is an association of PPAR gamma-2 Pro12Ala polymorphism with MS in 361 patients from Serbia. The genotype and allele frequencies of Pro12Ala polymorphism were not significantly different between controls and patients, or between females and males. In contrast to controls, we detected a rare Ala/Ala genotype in patients with MS. We found that there is a significant association of Ala/Ala genotype with older age at onset (ANOVA, p=0.07; LSD post-hoc, Ala/Ala vs. Pro/Ala, p=0.03, Ala/Ala vs. Pro/Pro p=0.02). It would be useful to validate our results in other populations, as well as to perform follow-up of the disease progression in regard to PPAR gamma genotypes.
T2  - Archives of Biological Sciences
T1  - The Ala/Ala Genotype of Pparγ Pro12 Ala Polymorphism Is Associated with Late Onset of Multiple Sclerosis
VL  - 65
IS  - 2
SP  - 447
EP  - 453
DO  - 10.2298/ABS1302447L
ER  - 

@article{
author = "Lukić, Nikola and Stanković, Aleksandra and Dinčić, Evica and Bundalo, Maja M. and Krsmanovic, Z. and Alavantić, Dragan and Živković, Maja",
year = "2013",
abstract = "The function of peroxisome proliferator-activated receptor gamma (PPAR gamma) in immune regulation, as well as in anti-inflammatory and anti-proliferative actions towards T lymphocytes, has been reported. A potential role of PPARs in multiple sclerosis (MS) was suggested. The aim of this study was to investigate if there is an association of PPAR gamma-2 Pro12Ala polymorphism with MS in 361 patients from Serbia. The genotype and allele frequencies of Pro12Ala polymorphism were not significantly different between controls and patients, or between females and males. In contrast to controls, we detected a rare Ala/Ala genotype in patients with MS. We found that there is a significant association of Ala/Ala genotype with older age at onset (ANOVA, p=0.07; LSD post-hoc, Ala/Ala vs. Pro/Ala, p=0.03, Ala/Ala vs. Pro/Pro p=0.02). It would be useful to validate our results in other populations, as well as to perform follow-up of the disease progression in regard to PPAR gamma genotypes.",
journal = "Archives of Biological Sciences",
title = "The Ala/Ala Genotype of Pparγ Pro12 Ala Polymorphism Is Associated with Late Onset of Multiple Sclerosis",
volume = "65",
number = "2",
pages = "447-453",
doi = "10.2298/ABS1302447L"
}

Lukić, N., Stanković, A., Dinčić, E., Bundalo, M. M., Krsmanovic, Z., Alavantić, D.,& Živković, M.. (2013). The Ala/Ala Genotype of Pparγ Pro12 Ala Polymorphism Is Associated with Late Onset of Multiple Sclerosis. in Archives of Biological Sciences, 65(2), 447-453.
https://doi.org/10.2298/ABS1302447L

Lukić N, Stanković A, Dinčić E, Bundalo MM, Krsmanovic Z, Alavantić D, Živković M. The Ala/Ala Genotype of Pparγ Pro12 Ala Polymorphism Is Associated with Late Onset of Multiple Sclerosis. in Archives of Biological Sciences. 2013;65(2):447-453.
doi:10.2298/ABS1302447L .

Lukić, Nikola, Stanković, Aleksandra, Dinčić, Evica, Bundalo, Maja M., Krsmanovic, Z., Alavantić, Dragan, Živković, Maja, "The Ala/Ala Genotype of Pparγ Pro12 Ala Polymorphism Is Associated with Late Onset of Multiple Sclerosis" in Archives of Biological Sciences, 65, no. 2 (2013):447-453,
https://doi.org/10.2298/ABS1302447L . .

TY  - JOUR
AU  - Đurić, Tamara
AU  - Đorđević, Ana
AU  - Lukić, Nikola
AU  - Anđelevski, Magdalena
AU  - Živković, Maja
AU  - Stanković, Aleksandra
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5188
AB  - Nitric oxide inhibits adhesion of thrombocytes, proliferation and migration of smooth muscle cells and restricts oxidation of atherogenic low-density lipoproteins. Therefore, decreased production or activity of NO may play a role in the initiation, progression or complications of atherosclerosis. The aim of this study was to estimate the effect of Glu298Asp eNOS gene polymorphism on the individual risk for development of complicated carotid atherosclerotic plaque in patients from Serbia with advanced carotid atherosclerosis (CA) who had undergone endarterectomy. The study population included 233 patients. eNOS G894T gene polymorphism was identified by PCR and RFLP methods. Multivariate logistic regression analysis showed that Asp298Asp is an independent risk factor for the presence of complicated plaques in CA patients. Patients who were homozygous for the Asp298 allele had an adjusted OR of 4.36 for the development of complicated plaques compared to those that carry the Glu298 allele. Further validation and replication studies are needed.
T2  - Archives of Biological Sciences
T1  - ENOS Glu298Asp Polymorphism Is Associated with Development of Complicated Plaques in Patients from Serbia with Advanced Carotid Atherosclerosis
VL  - 65
IS  - 1
SP  - 143
EP  - 149
DO  - 10.2298/ABS1301143D
ER  - 

@article{
author = "Đurić, Tamara and Đorđević, Ana and Lukić, Nikola and Anđelevski, Magdalena and Živković, Maja and Stanković, Aleksandra",
year = "2013",
abstract = "Nitric oxide inhibits adhesion of thrombocytes, proliferation and migration of smooth muscle cells and restricts oxidation of atherogenic low-density lipoproteins. Therefore, decreased production or activity of NO may play a role in the initiation, progression or complications of atherosclerosis. The aim of this study was to estimate the effect of Glu298Asp eNOS gene polymorphism on the individual risk for development of complicated carotid atherosclerotic plaque in patients from Serbia with advanced carotid atherosclerosis (CA) who had undergone endarterectomy. The study population included 233 patients. eNOS G894T gene polymorphism was identified by PCR and RFLP methods. Multivariate logistic regression analysis showed that Asp298Asp is an independent risk factor for the presence of complicated plaques in CA patients. Patients who were homozygous for the Asp298 allele had an adjusted OR of 4.36 for the development of complicated plaques compared to those that carry the Glu298 allele. Further validation and replication studies are needed.",
journal = "Archives of Biological Sciences",
title = "ENOS Glu298Asp Polymorphism Is Associated with Development of Complicated Plaques in Patients from Serbia with Advanced Carotid Atherosclerosis",
volume = "65",
number = "1",
pages = "143-149",
doi = "10.2298/ABS1301143D"
}

Đurić, T., Đorđević, A., Lukić, N., Anđelevski, M., Živković, M.,& Stanković, A.. (2013). ENOS Glu298Asp Polymorphism Is Associated with Development of Complicated Plaques in Patients from Serbia with Advanced Carotid Atherosclerosis. in Archives of Biological Sciences, 65(1), 143-149.
https://doi.org/10.2298/ABS1301143D

Đurić T, Đorđević A, Lukić N, Anđelevski M, Živković M, Stanković A. ENOS Glu298Asp Polymorphism Is Associated with Development of Complicated Plaques in Patients from Serbia with Advanced Carotid Atherosclerosis. in Archives of Biological Sciences. 2013;65(1):143-149.
doi:10.2298/ABS1301143D .

Đurić, Tamara, Đorđević, Ana, Lukić, Nikola, Anđelevski, Magdalena, Živković, Maja, Stanković, Aleksandra, "ENOS Glu298Asp Polymorphism Is Associated with Development of Complicated Plaques in Patients from Serbia with Advanced Carotid Atherosclerosis" in Archives of Biological Sciences, 65, no. 1 (2013):143-149,
https://doi.org/10.2298/ABS1301143D . .